RecruitingPhase 1NCT07349381

A Food-Effect Study of CX11 in Healthy Participants

An Open-label, Randomized, Multiple-dose, Two-cycle, Two-way Crossover Phase 1 Study to Evaluate the Effect of Food on the Pharmacokinetics of CX11 Tablets in Healthy Participants

Sponsor

Vincentage Pharma Co., Ltd

Enrollment

32 participants

Start Date

Mar 4, 2026

Study Type

INTERVENTIONAL

Conditions

Obesity, Overweight Type 2 Diabetes

Summary

This study is to evaluate the food effect (FE) on the PK of 200 mg CX11 in healthy participants

Eligibility

Min Age: 18 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called CX11 (VCT220) for people with obesity, overweight and type 2 diabetes. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 45 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCX11 (VCT220)

CX11 (VCT220) administered orally to participants who are in fasted/fed state in the first 6 consecutive days, and in fed/fasted state on the 7th day

Locations(1)

Shanghai Xuhui Central Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07349381

Related Trials

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

NCT0673912251 locations

A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

NCT076520472 locations